File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

TitlePembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Authors
Cortes, JCescon, DWRugo, HSNowexcki, ZIm, SAKwong, AKarantza, VSchmid, P
Issue Date2020
Citation
The Lancet, 2020, v. 396, p. 1817-1828 How to Cite?
DOI: http://dx.doi.org/10.1016/S0140-6736(20)32531-9
Persistent Identifierhttp://hdl.handle.net/10722/312789

 

DC FieldValueLanguage
dc.contributor.authorCortes, J-
dc.contributor.authorCescon, DW-
dc.contributor.authorRugo, HS-
dc.contributor.authorNowexcki, Z-
dc.contributor.authorIm, SA-
dc.contributor.authorKwong, A-
dc.contributor.authorKarantza, V-
dc.contributor.authorSchmid, P-
dc.date.accessioned2022-05-12T10:55:36Z-
dc.date.available2022-05-12T10:55:36Z-
dc.date.issued2020-
dc.identifier.citationThe Lancet, 2020, v. 396, p. 1817-1828-
dc.identifier.urihttp://hdl.handle.net/10722/312789-
dc.languageeng-
dc.relation.ispartofThe Lancet-
dc.titlePembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial-
dc.typeArticle-
dc.identifier.emailKwong, A: avakwong@hku.hk-
dc.identifier.authorityKwong, A=rp01734-
dc.identifier.doi10.1016/S0140-6736(20)32531-9-
dc.identifier.hkuros333008-
dc.identifier.volume396-
dc.identifier.spage1817-
dc.identifier.epage1828-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats